Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.
Keywords: Pharmacogenomic; cisplatin; gemcitabine; lung cancer chemotherapy; pemetrexed; polymorphism patents; taxanes; vinorelbine.
Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.